ModifiedUnitedHealthcarePolicy CS015NE.W

Cardiovascular Disease Risk Tests (for Nebraska Only)

Defines medical policy for use and coverage stance of noninvasive arterial compliance testing, carotid intima-media thickness (CIMT), advanced lipoprotein analyses, Lp-PLA2, and multiprotein/algorithmic cardiovascular risk biomarker tests for members in Nebraska.

Policy Summary

PayerUnitedHealthcare

PolicyCardiovascular Disease Risk Tests (for Nebraska Only)

Policy CodePolicy CS015NE.W

Change TypeRevised content and archived prior version

Effective DateMay 1, 2026

Next Review Date

Key ActionVerify prior authorization requirements and document how test results will change patient management when ordering advanced lipoprotein, Lp(a), multiprotein, or endothelial function tests.

SourceLink

POLICY UPDATE CHANGES

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.

NebraskaState-limited

>=10Unproven tests

MultipleCodes referenced

LargeSystematic reviews cited

0–minimal

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Incremental prediction

Coverage Criteria and Evidence Summary

Unproven / Not Medically Necessary

The following tests are considered unproven and not medically necessary due to insufficient evidence that they improve management or clinical outcomes:

Unproven tests list: Arterial compliance testing using waveform analysis; carotid intima-media thickness (CIMT) measurement as a screening tool for management of cardiovascular disease; advanced lipoprotein analysis (including lipoprotein(a), subfractions, or particle size); lipoprotein-associated phospholipase A2 (Lp-PLA2) enzyme testing for CVD or ischemic stroke risk; endothelial function assessment using peripheral arterial tonometry (PAT) or brachial artery ultrasound; multiprotein diagnostic biomarker assays including: analysis of protein biomarkers by aptamer-based microarray with algorithm; cholesterol efflux capacity (HDL reverse cholesterol transport) measured by LC-MS/MS with quantitative measurement of five HDL-bound apolipoproteins and an algorithmic risk score; a three-protein panel (high-sensitivity troponin, adiponectin, KIM-1) with algorithmic risk score; a four-protein panel (NT-proBNP, osteopontin, TIMP-1, KIM-1) with algorithmic risk score; and a seven-protein panel (IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, MCP-3) with algorithmic risk score.

These specific tests are listed as unproven and not medically necessary in the policy (insufficient evidence of efficacy).

Evidence summaries for CIMT, advanced lipoproteins, and Lp(a)

Evidence-based findings and limitations relevant to coverage decisions

CIMT evidence summary: CIMT is associated with coronary heart disease, incident carotid plaque, and some cardiovascular outcomes across multiple cohorts and meta-analyses, but measurement definitions and methods vary widely; studies show only modest incremental reclassification beyond traditional risk factors, and there is inadequate evidence that routine measurement of CIMT alters management or improves clinical outcomes.

Supported by prospective cohorts, systematic reviews, and meta-analyses noting heterogeneity and lack of demonstrated impact on care (see cited studies).

Advanced lipoprotein testing: Advanced lipoprotein markers (apoB, Lp(a), Lp-PLA2, particle number/size) have inconsistent incremental predictive benefit over standard lipid measures; large pooled analyses found that replacing total cholesterol and HDL-C with these markers did not significantly improve CVD risk prediction, and standardized testing modalities are lacking.

Emerging Risk Factors Collaboration and other reviews highlight inconsistent incremental value and need for larger prospective studies.

Lipoprotein(a) evidence: Lp(a) is independently associated with increased ASCVD and stroke risk in multiple cohort analyses and meta-analyses and is relatively stable over time; however, heterogeneity in thresholds by population and limited evidence that measurement changes clinical management or outcomes limits routine utility for all patients.

Large individual-level meta-analyses and multi-cohort studies show consistent association but do not demonstrate that testing improves outcomes.

Evidence summary and clinical utility caveat

Summary of evidence-based considerations for testing:

Evidence and clinical utility: Observational cohorts and systematic reviews associate elevated Lp(a) and elevated Lp-PLA2 with higher risk of ASCVD events and stroke subtypes, and multiprotein biomarker panels correlate with outcomes; however, studies vary in thresholds, populations, and outcomes, and critically do not demonstrate that testing results lead to changes in management or improved clinical outcomes.

Heterogeneity and limited clinical utility evidence are recurring limitations across biomarker and vascular marker studies.

Multiprotein blood tests

Proprietary or multiprotein score testing:

Proprietary multiprotein tests: Multiprotein blood tests and algorithm-derived risk scores show associations with cardiovascular outcomes in derivation and validation cohorts, but there is a lack of high-quality peer-reviewed clinical utility studies demonstrating that use of these proprietary scores improves management decisions or patient outcomes; specific assays (for example HART CADhs) currently lack sufficient published evidence for routine clinical adoption.

Evidence briefs and cohort analyses report correlations but not demonstrated impact on care; clinical utility data are insufficient.

Summary coverage logic and clinical guidance

Evidence and guideline-based positions summarized:

Endothelial function assessment: Routine measurement of endothelial function (PAT or brachial flow‑mediated dilation) is not supported by sufficient evidence to demonstrate clinical utility for cardiovascular risk assessment and should not be used for routine screening or to guide therapy in asymptomatic adults.

Cohort studies show conflicting associations and guidelines do not support routine use.

Multiprotein biomarker panels/CEC: Cholesterol efflux capacity and multiprotein biomarker scores are associated with CAD and adverse events in research settings, but assay standardization, variable cutoffs, and lack of demonstrated outcome benefit limit their use to research or contexts where a clear intended management change is documented.

Validation AUCs reported in some studies but no proven effect on outcomes.

Advanced lipoprotein testing (apoB, Lp(a), Lp‑PLA2): Guideline recommendations vary: targeted measurement of Lp(a) and apoB is recommended by some societies in selected clinical situations (family history of premature ASCVD, unexplained or premature ASCVD, discordant LDL-C/apoB), but routine advanced lipoprotein testing for all asymptomatic adults is not recommended and expanded lipid panels (particle sizing/NMR) are discouraged for routine screening.

Use of Lp(a), apoB, and advanced lipoprotein tests

Coverage and clinical-use considerations summarized from guideline and society statements in the document.

Lp(a) testing: Measure Lp(a) at least once in an adult's lifetime to aid lifetime risk stratification; consider Lp(a) ≥ 50 mg/dL (≈125 nmol/L) as a risk-enhancing factor to reclassify cardiovascular risk, particularly in individuals near treatment thresholds or with a family history of premature ASCVD.Lp(a) risk thresholds per ESC/EAS and NLA

ESC/EAS and NLA recommend at least one lifetime measurement and define low/intermediate/high risk categories; use results to inform intensified risk-factor management where appropriate.

ApoB testing: ApoB measurement is recommended by professional societies (NLA, ESC/EAS) for improved risk assessment in selected populations (discordant LDL-C/apoB, high triglycerides, diabetes, obesity, metabolic syndrome) because apoB better reflects atherogenic particle number in these contexts.None specified

Use apoB to refine risk when standard lipid measures are discordant.

Noninvasive vascular tests (ABI, CAC, endothelial function)

Guidance on vascular markers and screening utility.

Ankle-Brachial Index (ABI): USPSTF concluded evidence is insufficient to assess benefits and harms of screening asymptomatic adults with ABI; VA/DoD guidelines suggest against routine use of additional risk markers (eg, ABI, CAC) when assessing cardiovascular risk.Not applicable

ABI screening in asymptomatic populations is not clearly supported by current evidence.

Endothelial function devices (e.g., Endo PAT): Some endothelial function devices (for example Endo PAT 2000) have received FDA 510(k) clearance for diagnostic aid in symptomatic patients, but FDA device clearance is informational and does not establish that these devices are appropriate for routine population screening or that testing improves outcomes.Not applicable

Device clearance alone is not a basis for coverage decisions; clinical utility for screening is unproven.

The inclusion of a procedure or proprietary code in this policy is for reference only. Listing a code does not imply that the service described by the code is a covered or non-covered benefit, nor does it guarantee reimbursement. Coverage and payment are determined by the member's applicable federal, state, or contractual benefit terms and applicable laws.

Tests performed solely for general cardiovascular risk screening without documentation that results will alter clinical management may be excluded. Evidence for measures such as carotid intima-media thickness demonstrates association with cardiovascular outcomes but does not show that routine screening with these tests changes management or improves outcomes; documentation must show how results will influence care to support medical necessity.

Proprietary multiprotein or algorithmic blood tests reported as a single risk score are not supported for routine screening or management decisions when they lack peer-reviewed evidence of clinical utility. Available studies show correlations with outcomes but do not demonstrate that these scores improve patient management or clinical outcomes; such tests require robust clinical utility data before being used to guide care.

The American Society for Clinical Pathology (ASCP) recommends against routinely ordering expanded lipid panels (for example, particle sizing or NMR-based panels) as screening tests for cardiovascular disease. Routine expanded lipid panels for screening are discouraged and may be subject to noncoverage review.

Advanced or expanded lipid panels, including particle sizing, NMR-based LDL particle number, small dense LDL-C, and related assays, are not standardized across laboratories and have inconsistent evidence of incremental predictive value beyond conventional lipid measures. Because of this lack of standardization and unproven incremental clinical utility, routine use of these expanded lipid tests for screening is not supported.

This Medical Policy is provided for informational purposes and does not constitute medical advice. Coverage for any service described in this policy is subject to the member's federal, state, or contractual benefit plan, and those applicable terms govern in the event of any conflict.

The tests addressed by this policy include noninvasive arterial compliance/waveform analysis, carotid intima-media thickness (CIMT), advanced lipoprotein analyses (including particle sizing and NMR), apolipoprotein B and Lp(a) measurement, Lp-PLA2 enzyme testing, endothelial function assessment (e.g., PAT, brachial artery flow-mediated dilation), and specified multiprotein algorithmic biomarker assays. These tests are discussed with respect to their evidence base and intended clinical roles; specific CPT/PLA and procedure codes are listed in the coding section for reference only.

Routine use of the tests described in this policy as replacements for established risk-assessment approaches (for example, global risk scores and standard lipid measurements) is not supported. The evidence generally shows at best minimal incremental prediction beyond traditional risk factors and lacks demonstration that test-directed strategies improve clinical outcomes; therefore these tests should not routinely replace established assessment and management pathways.

Biomarkers or multiplex panels that provide only minimal or no incremental improvement in ASCVD risk prediction over established risk factors (such as total cholesterol, HDL-C, and validated clinical risk scores) are insufficient to establish clinical utility. Measurement alone, without evidence that results change management or improve outcomes, does not meet medical necessity criteria.

Endothelial function testing methods, including peripheral arterial tonometry (PAT) and brachial artery flow‑mediated dilation, have shown inconsistent associations with cardiovascular outcomes across cohort studies and do not demonstrate adequate clinical utility for routine risk stratification in asymptomatic individuals. As a result, these assessments are not supported for routine screening or to guide therapy unless specific, documented circumstances justify their use.

Professional society guidance and evidence reviews note that routine ordering of expanded lipid panels (particle sizing or NMR) is discouraged for screening purposes. Additionally, lack of assay standardization and inconsistent incremental predictive value limit the utility of these tests for routine cardiovascular risk assessment.

Coding, Thresholds, and Key Values

Referenced proprietary and lab CPT/PLA codesmixed

0019M	Cardiovascular disease, plasma, analysis of protein biomarkers by aptamer-based microarray and algorithm reported as 4-year likelihood of coronary event in high-risk populations.
0052U	Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation.
0308U	Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (hs troponin, adiponectin, KIM-1) with 3 clinical parameters, plasma, algorithm reported as a risk score for obstructive CAD.
0309U	Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, TIMP-1, KIM-1), plasma, algorithm reported as a risk score for major adverse cardiac event.
0377U	Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by NMR spectrometry with report of a lipoprotein profile (including 23 variables).
0415U	Cardiovascular disease (ACS), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with clinical variables, algorithm reported as a 5-year score for ACS.
0541U	Cardiovascular disease (HDL reverse cholesterol transport), cholesterol efflux capacity, LC-MS/MS, quantitative measurement of 5 distinct HDL-bound apolipoproteins, algorithm reported as prediction of coronary artery disease score.
83695	Lipoprotein (a).
83698

Referenced lab and vascular procedure codesmixed

83701	Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed.
83704	Lipoprotein, blood; quantitation of lipoprotein particle number(s) (e.g., by NMR), includes lipoprotein particle subclass(es), when performed.
93050	Arterial pressure waveform analysis for assessment of central arterial pressures, includes obtaining waveform(s), digitization and application of nonlinear mathematical transformations to determine central arterial pressures and augmentation index, with interpretation and report, upper extremity artery, non-invasive.
93799	Unlisted cardiovascular service or procedure.
93895	Quantitative carotid intima media thickness and carotid atheroma evaluation, bilateral.
93998	Unlisted noninvasive vascular diagnostic study.

FDA product codes mentionedmixed

DXN	FDA product code category for noninvasive blood pressure measurement system products (informational)
IYO	FDA product code for B-mode ultrasound equipment used for carotid intima-media thickness (informational)
DFC	FDA product code for lipoprotein(a) measurement products (informational)
NOE	FDA product code for Lp-PLA2 measurement products (informational)
JJX	FDA product code for Lp-PLA2 measurement products (informational)

Device 510(k) clearancesmixed

K032519	Endo PAT 2000 510(k) clearance (informational)
K001852	PAT 1000 RD predicate device listed in Endo PAT 2000 clearance (informational)
K122129	SphygmoCor XCEL System 510(k) clearance (informational)

cfPWV cutoff — closest cutoff points

cfPWV cutoff for cardiovascular mortality10.7 m/s (closest cutoff point to pooled summary for cardiovascular mortality)

cfPWV cutoff for all-cause mortality11.5 m/s (closest cutoff point to pooled summary for all-cause mortality)

cfPWV evidence contextDerived from systematic review/meta-analysis (Sequí-Domínguez et al. 2020) of longitudinal studies; authors note limitations including heterogeneity and lack of reported incremental clinical utility.

CIMT cutoff for CAD diagnostic accuracy

CIMT diagnostic cutoff for CAD1 mm (identified as a more accurate diagnostic criterion in meta-analysis subgroup analyses)

Provider Actions, Prior Authorization, and Documentation

Documentation Required

Provider Actions — Codes, Authorization, and Conflicting Benefit Terms

Providers: Verify applicable codes listed in the policy are for reference only and do not guarantee coverage or reimbursement. Always check the member's plan and benefit contract for coverage, prior authorization, and billing requirements before ordering or performing tests. This policy is informational; federal, state, or contractual benefit terms govern in the event of a conflict.

Applicable codes (see Related Policy / Applicable Codes) are provided for reference only and may not be all-inclusive; inclusion does not imply coverage or payment.
Before ordering, confirm prior authorization requirements and coverage under the member's specific benefit plan; authorization rules may vary by contract and state.
When coverage terms conflict with this policy, federal, state, or contractual requirements take precedence.

Note

Provider Actions — Device Clearance Informational

Device clearance and FDA information in this policy are provided for informational purposes only. FDA clearance or predicate device listings do not imply that a device-based test is covered by a given plan. Coverage decisions are made based on medical necessity, benefit terms, and applicable contractual requirements.

Background and Rationale

Cardiovascular diseases, including coronary artery disease, stroke, and hypertension, are leading causes of morbidity and mortality. A range of noninvasive tests and biomarkers (for example, arterial compliance/PWV, carotid intima-media thickness, advanced lipoprotein measures, Lp-PLA2, endothelial function testing, and multiprotein algorithmic assays) have been proposed to improve risk stratification. While many of these measures are associated with cardiovascular risk in observational studies and cohort analyses, the clinical evidence is generally insufficient to show that routine use of these tests improves clinical decision-making or patient outcomes, and measurement heterogeneity and lack of standardization further limit their applicability in routine care.

Definitions and Test Descriptions

Carotid intima-media thickness (CIMT) — definition

CIMT definitionCarotid intima-media thickness (CIMT) is a noninvasive ultrasound measurement of carotid artery wall thickness (intima and media layers) used as a subclinical atherosclerosis marker and predictor of cardiovascular events.

Measurement techniquesCIMT uses high-resolution ultrasound imaging and software analysis; studies report variability in measurement definitions (mean vs maximum CIMT) and lack standardization.

Clinical interpretation caveatAlthough associated with CHD and incident carotid plaque, CIMT provides modest incremental reclassification beyond traditional risk factors and its impact on management/outcomes is uncertain.

Arterial compliance / pulse wave velocity (PWV) — definition

PWV / arterial compliance definitionArterial compliance measures (e.g., pulse wave velocity [PWV], augmentation index) assess arterial stiffness and vascular aging via waveform analysis; carotid-femoral PWV (cfPWV) is commonly used as a noninvasive predictor of cardiovascular risk.

Revision History and Policy Changes

2026-05-01policy_effective_dateLatest

Policy revision effective; updated Description of Services, Clinical Evidence, and References sections and archived prior version CS015NE.V.

Policy Summary

PayerUnitedHealthcare

PolicyCardiovascular Disease Risk Tests (for Nebraska Only)

Policy CodePolicy CS015NE.W

Change TypeRevised content and archived prior version

Effective DateMay 1, 2026

Next Review Date

Key ActionVerify prior authorization requirements and document how test results will change patient management when ordering advanced lipoprotein, Lp(a), multiprotein, or endothelial function tests.

SourceLink

On This Page

Professional society statements support selective testing rather than routine population screening.

Advanced lipoprotein tests (particle number, NMR, small dense LDL, remnant cholesterol): These advanced lipoprotein tests lack standardization and conclusive evidence of added CVD prediction beyond standard lipid measures; societies (ASCP) recommend against routine ordering of expanded lipid panels for screening, and these tests should be reserved for selected, documented circumstances.Not applicable

Routine screening with expanded lipid panels is discouraged.

CIMT sensitivity/specificityPooled sensitivity ~0.66–0.68 and specificity ~0.70–0.79 at cutoff ~1 mm

CIMT evidence caveatMeta-analysis authors noted heterogeneity and did not address clinical utility for improving outcomes or management.

Net reclassification index ranking

Net reclassification index ranking — highestCoronary artery calcium (CAC): ≥ 11.2% (highest NRI)

Net reclassification index — carotid plaqueCarotid plaque: ≥ 2% (second-ranked NRI)

Net reclassification index — CIMTCIMT: 3% (lower-ranked NRI)

Lp(a) abnormal threshold

Lp(a) abnormal threshold (ATTICA cohort)≥ 50 mg/dL (used as the recommended threshold in the ATTICA prospective cohort analysis)

ATTICA cohort findings10-year CVD event rates were 14% (<50 mg/dL) vs 24% (≥50 mg/dL); multivariate HR ≈2.18 for Lp(a) ≥50 mg/dL

Population contextATTICA included community-dwelling adults free of CVD; sensitivity analyses showed effect modification by lipid profile and diet in women vs men.

Lp(a) percentile risk stratification

Elevated Lp(a) — BiomarCaRE percentile 67th–89th67th–89th percentile: associated with increased risk (HR ~1.25–1.30 for MCEs/CVD)

Elevated Lp(a) — BiomarCaRE >90th percentile>90th percentile: associated with higher risk (HR ~1.44–1.49 for MCEs/CVD)

BiomarCaRE cohort size/contextAnalysis of 56,804 participants from seven prospective population-based cohorts with median ~8.7–8.8 years follow-up

Natriuretic peptide abnormal thresholds

BNP abnormal thresholdBNP ≥ 50 pg/mL

NT-proBNP abnormal thresholdNT‑proBNP ≥ 125 pg/mL

Clinical contextADA 2024 update: thresholds suggested for screening asymptomatic adults with diabetes; abnormal levels require contextual clinical evaluation.

Lp(a) and apoB thresholds called out in guidelines

Guideline Lp(a) thresholdLp(a) ≥ 50 mg/dL (≥125 nmol/L) considered a risk-enhancing factor per ACC/AHA and other societies

Guideline apoB thresholdApoB ≥ 130 mg/dL considered a risk-enhancing factor (corresponds roughly to LDL‑C >160 mg/dL)

Indications for testingSociety statements recommend measuring Lp(a) and apoB in select populations (family history of premature ASCVD, discordant lipids, high triglycerides) rather than universally.

Lp(a) risk thresholds (mg/dL and nmol/L conversions)

Lp(a) low riskLow: < 30 mg/dL (<75 nmol/L)

Lp(a) intermediate riskIntermediate: 30–50 mg/dL (75–125 nmol/L)

Lp(a) high riskHigh: ≥ 50 mg/dL (≥125 nmol/L)

Lp(a) very high lifetime riskVery high: > 180 mg/dL (>430 nmol/L) — may confer lifetime risk comparable to heterozygous familial hypercholesterolemia

Noninvasive device clearances (e.g., EndoPAT 2000, SphygmoCor systems) are listed for information; check device product codes and 510(k) summaries as needed.
Measurement procedures that are not device-regulated (e.g., CIMT as a procedure) may not be subject to FDA listing — consult benefit terms for coverage.

Documentation Required

Provider Actions — Multiprotein Risk Score Documentation

Multiprotein risk scores and proprietary algorithm-based panels currently lack sufficient peer-reviewed evidence of clinical utility to support routine coverage. When these tests are requested, include documentation that addresses evidence of clinical utility and how results will change management.

Document clinical indication, baseline risk, and how the test result will change patient management (e.g., alter therapy selection or intensity).
Provide peer-reviewed evidence supporting clinical utility when requesting prior authorization for proprietary multiprotein tests (e.g., HART CADhs, Prevencio).
Tests with algorithm-reported risk scores (e.g., 0019M, 0308U, 0309U, 0415U, 0541U) are subject to review for demonstrated impact on clinical outcomes.

Step Therapy

Provider Actions — Stepwise Management Before Specialized Interventions

Use a stepwise approach before initiating specialized Lp(a)-directed or other novel therapies. Standard risk-factor modification and guideline-directed LDL-C lowering should be optimized first; specialized interventions or testing should be considered when results would meaningfully change management.

Ensure lifestyle modification and maximally tolerated guideline-directed LDL-C lowering are documented before specialized Lp(a)-targeted interventions are considered.
Document why additional testing (e.g., Lp(a), apoB) is expected to change management beyond standard care.

Prior Authorization

Provider Actions — Use Established Biomarkers First

Established biomarkers should be used first for cardiovascular risk assessment. Advanced or expanded testing (e.g., NMR particle sizing, routine expanded lipid panels, endothelial function testing) should be reserved for situations where established markers do not adequately inform risk and when results will change management.

Consider standard lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) and clinical risk scores before ordering advanced tests.
Reserve advanced lipid testing or endothelial function assessment for selected cases with documented rationale and likely impact on treatment decisions.

Documentation Required

Provider Actions — Use of apoB and Lp(a) in Risk Stratification

ApoB and Lp(a) measurement may be useful for risk stratification in selected populations. When ordered, document the specific indication (e.g., discordant LDL-C and apoB, strong family history of premature ASCVD, cascade screening), and how results will influence therapy.

Indications that may support testing: unexplained premature ASCVD, familial hypercholesterolemia evaluation, discordant LDL-C/apoB results, or cascade screening of first-degree relatives.
Document how test results will change management (e.g., intensification of LDL-C lowering, referral for specialty care, or cascade family testing).
One-time measurement of Lp(a) is generally sufficient per guideline recommendations; note this in documentation if applicable.

Documentation Required

Provider Actions — Documentation and Decision Support

Documentation and decision-support resources should be provided with requests for low-utility or emerging tests. Include clinical indication, baseline risk assessment, relevant prior tests and therapies, and a clear statement of how the test result will alter clinical management.

Include patient demographics, relevant history (ASCVD, risk factors), current therapies (e.g., statin intensity and LDL-C levels), and prior relevant test results.
Cite guideline recommendations or peer-reviewed evidence supporting the proposed test's use in the clinical scenario.
When applicable, reference the member's benefit terms or prior authorization criteria and attach supporting literature to expedite review.

Measurement methodsWaveform analysis uses central and peripheral pressure waveforms and derived indices; methods include noninvasive blood pressure waveform digitization and mathematical transformations.

Clinical evidence noteSystematic reviews show cfPWV predicts cardiovascular and all-cause mortality, but study heterogeneity and lack of reported incremental clinical utility limit routine clinical adoption.

Lp-PLA2 — definition

Lp-PLA2 definitionLipoprotein-associated phospholipase A2 (Lp-PLA2) is a vascular inflammatory enzyme measured as mass or activity and investigated as a biomarker for coronary heart disease and ischemic stroke risk.

Measurement formsLp-PLA2 can be reported as activity or mass; studies vary in assay methods and thresholds, contributing to heterogeneity in evidence.

Clinical utility noteMeta-analyses associate higher Lp-PLA2 with increased stroke risk, but evidence quality is low and clinical utility for changing management is unproven.

Multiprotein algorithmic tests — definition

Multiprotein algorithmic test definitionProprietary multiprotein algorithmic tests combine measurements of several protein biomarkers with an algorithm (often proprietary/AI) to produce a risk score for obstructive coronary disease or future cardiovascular events (examples: aptamer-based microarray tests, HART panels, CEC-based algorithms).

Commercial examplesExamples include aptamer-based proteomic assays with an algorithmic report (0019M), HART CADhs/HART CVE panels, and CEC-based LC-MS/MS assays (0541U).

Evidence caveatPublished studies show associations with outcomes but lack demonstrated clinical utility in improving management or outcomes; assay standardization and external validation are often limited.

Carotid intima-media thickness (CIMT) — alternate references

CIMT alternate definitionUltrasound measurement of the thickness of the carotid artery intima and media layers used as a subclinical atherosclerosis marker and predictor of future cardiovascular events.

Measurement variabilityStudies report mean common carotid artery IMT (CCA-IMT) around 0.71 mm in cohorts; measurement definitions (mean vs max IMT) differ across studies.

LimitationsHeterogeneity in measurement techniques and equipment (older vs newer ultrasound devices) limit comparability across studies.

Lipoprotein(a) (Lp(a)) — definition

Lp(a) definitionLipoprotein(a) (Lp(a)) is a genetically determined lipoprotein particle associated with increased risk of atherosclerotic cardiovascular disease; levels are relatively stable and vary by race/ethnicity.

Clinical significanceMultiple cohort studies and meta-analyses demonstrate associations between elevated Lp(a) and ASCVD outcomes, but heterogeneity in thresholds and limited evidence that measurement changes outcomes are noted.

Measurement considerationsGuidelines recommend targeted measurement for risk stratification (family history of premature ASCVD, unexplained ASCVD) and at least once in life per some societies.

Lp(a) — additional definition and context

Lp(a) context and stabilityLp(a) levels are largely genetically determined and relatively stable over time; elevated levels are linked to higher risk of MCEs and CVD in large population cohorts.

Evidence limitationsHeterogeneity in Lp(a) thresholds across studies and differences in assay/storage introduce variability; repeated measures and regression-dilution adjustments are limited.

Population observationsSome analyses (e.g., BiomarCaRE) show stronger Lp(a)-associated risk in participants with diabetes.

Lp-PLA2 — mass or activity measurement definition

Lp-PLA2 measurement formsLp-PLA2 can be measured as mass or activity; meta-analyses report relative risks per SD increase and for highest vs lowest categories.

Association with strokeMeta-analyses indicate elevated Lp-PLA2 activity/mass is associated with higher risk of overall stroke and ischemic stroke (RRs modestly >1).

Assay heterogeneity caveatNonuniform test methods across studies limit comparability and clinical interpretability; clinical utility remains unproven.

Multiprotein blood test with algorithm — commercial definition

Commercial multiprotein algorithmic blood testsCommercial assays combine multiple biomarker measurements with proprietary algorithms to produce a risk score (reported CPT/PLA examples: 0019M, 0308U, 0309U, 0415U, 0541U).

Algorithmic reportingResults are reported as algorithm-derived risk scores for obstructive CAD, ACS, or future major adverse cardiac events, often requiring external validation.

Evidence limitationsAvailable studies show associations but do not demonstrate that test-guided strategies alter management or improve outcomes; peer-reviewed clinical utility evidence is limited.

Cholesterol efflux capacity (CEC) — definition

Cholesterol efflux capacity (CEC) definitionCholesterol efflux capacity (CEC) is a laboratory measure of HDL functional ability to remove cholesterol from macrophages, reported as an HDL functional metric rather than a concentration.

Associations with CADMeta-analyses show lower CEC is associated with higher risk of CAD; higher CEC linked to reduced adverse cardiovascular events in pooled analyses.

Standardization caveatAssay methods and cutoff values for CEC vary across studies; incremental clinical utility and impact on outcomes remain unproven.

Peripheral arterial tonometry (PAT) / Reactive hyperemia index (RHI)

PAT / RHI definitionPeripheral arterial tonometry (PAT) measures fingertip pulse amplitude before and after occlusion; Reactive Hyperemia Index (RHI) is the post-to-preocclusion pulse amplitude ratio (occluded arm relative to control arm) used to quantify microvascular endothelial function.

Clinical measurement detailsPAT records finger arterial pulse wave amplitude during reactive hyperemia in short intervals; studies link RHI variably to stroke risk but not consistently to composite CVD outcomes.

Evidence limitationsLarge cohort analyses report inconsistent associations with incident composite CVD events; clinical utility for routine screening is not established.

Lp(a) — definition reiteration (ASCVD and aortic valve stenosis risk)

Lp(a) reiterated definitionLp(a) is a genetically determined lipoprotein associated with increased ASCVD and aortic valve stenosis risk; screening is particularly recommended for those with family or personal history of premature ASCVD, and some societies recommend at least one lifetime measurement.

Clinical implicationElevated Lp(a) may be used as a risk modifier to reclassify risk and guide intensification of standard risk factor management pending availability of targeted therapies.

Guideline supportAHA scientific statement supports causal role of Lp(a) and potential to inform management, with screening strongest in those with family/personal history of ASCVD.

ApoB — definition and guideline context

ApoB definitionApolipoprotein B (apoB) is a measure of the number of atherogenic particles and is recommended by NLA as superior to LDL‑C for risk assessment in certain contexts (e.g., discordant LDL-C/apoB), especially when triglycerides are elevated.

Clinical recommendationNLA endorses apoB measurement to improve risk assessment and to guide diagnosis of lipoprotein phenotypes and family cascade screening.

Relationship to LDL-CApoB may better align with ASCVD risk than LDL-C when discordant; a threshold ≥130 mg/dL is considered risk-enhancing per society statements.

Advanced lipoprotein testing — examples and recommendation

Advanced lipoprotein testing examplesIncludes particle sizing, NMR LDL particle number, small dense LDL-C, and remnant cholesterol assays.

Standardization and recommendationThese tests are not standardized across platforms and are not routinely recommended for screening (ASCP recommends against routine expanded lipid panels).

Clinical roleMay be considered selectively after initial lipid evaluation in certain patients, but routine use for population screening is discouraged.

Referenced cardiovascular risk tests

Referenced cardiovascular risk tests listReferenced tests include: Lipoprotein(a) (Lp(a)); pulse wave velocity (PWV)/arterial compliance; peripheral arterial tonometry (PAT)/Reactive Hyperemia Index (RHI); carotid intima-media thickness (CIMT); Lp-PLA2; cholesterol efflux capacity (CEC); multiprotein algorithmic biomarker panels.

Evidence summaryThese biomarkers and noninvasive tests show associations with cardiovascular outcomes in observational studies and meta-analyses but generally provide minimal incremental prediction over established risk factors and lack proven clinical utility to change management.

Policy implicationMost are considered unproven/not medically necessary for routine screening or management absent documentation that test results will alter care.